Neogenomics Inc cash flow statement
In fiscal 2025, Neogenomics Inc's operations generated $5.2m of cash; it spent $27.0m on capital projects, leaving free cash flow of −$21.8m.
Cash flow statement
| Fiscal year | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMSept 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 21 | 18 | 45 | 23 | 1 | −27 | −66 | −2 | 7 | 5 | 4 |
| Depreciation and amortisation | 16 | 16 | 16 | 20 | 26 | 30 | 35 | 37 | 39 | 36 | 35 |
| Stock-based pay | 5 | 6 | 7 | 10 | 10 | 22 | 25 | 25 | 33 | 41 | 35 |
| Capital spending | 8 | 14 | 14 | 20 | 29 | 64 | 31 | 29 | 41 | 27 | 33 |
| Free cash flow | 14 | 4 | 30 | 3 | −28 | −91 | −97 | −31 | −34 | −22 | −29 |
| Free cash flow after stock pay | 9 | −2 | 24 | −7 | −38 | −113 | −122 | −55 | −67 | −63 | −63 |
| Shares issued | — | 3 | 9 | 11 | 20 | 15 | 13 | 5 | 5 | 1 | 0 |
| Quarter | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 | 2026 Q3Sept 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 10 | −25 | 20 | 9 | 1 | −8 | 20 | −9 |
| Depreciation and amortisation | 10 | 9 | 9 | 9 | 9 | 9 | 9 | 9 |
| Stock-based pay | 8 | 11 | 12 | 10 | 8 | 10 | 8 | 9 |
| Capital spending | 12 | 5 | 6 | 8 | 8 | 5 | 8 | 12 |
| Free cash flow | −2 | −30 | 14 | 1 | −7 | −13 | 12 | −21 |
| Free cash flow after stock pay | −10 | −41 | 2 | −10 | −15 | −23 | 4 | −29 |
| Shares issued | 1 | 1 | 1 | 1 | −2 | −0 | 2 | 1 |
Compare with peers
- Repligen Corp cash flow
- 10x Genomics, Inc. cash flow
- Azenta, Inc. cash flow
- Veracyte, Inc. cash flow
- Bio-Techne cash flow
Head to head: NEO vs RGENNEO vs TXGAZTA vs NEONEO vs TECH
More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies